mm

About Josh Conway

Josh is a professional editor and is responsible for editing our articles before they become available to the public as well as moderating our Discord server. He is also a programmer, long-time supporter of rejuvenation biotechnology, and avid player of the strange game called "real life." Living in the center of the northern prairie, Josh enjoys long bike rides before the blizzards hit.
Posts from the author

A recent open-access study published in Cell Stem Cell has shown that excluding Oct4 from the OSKM cocktail reduces epigenetic aberrations and off-target gene activation. Induced pluripotency and Yamanaka factors Pluripotent stem cells are cells that can become other cell types in the body; during natural development, they create differentiated stem cells and ultimately somatic…

This is the final talk that we are releasing from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. João Pedro de Magalhães of the University of Liverpool discussed the genetic basis of aging and…

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. Sree Kant of Life Biosciences discussed investment and R&D in an aging world, demonstrating the necessity of rejuvenation biotechnology in…

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. Kevin Strange discussed his company, Novo Biosciences, and how it is developing small molecules that restore the body’s ability to…

On Friday, October 25, we hosted a Q&A webinar with the team behind MitoMouse, the second MitoSENS program that we are funding. In this webinar, Drs. Aubrey de Grey, Amutha Boominathan, and Matthew “Oki” O’Connor answered viewer questions about the nature of their research and the SENS approach to age-related disease. There are only a…

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. Joe Betts-LaCroix discussed the prioritization of aging compared to other government programs, the relationship between finance and human health, funding…

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. Vadim Gladyshev of Harvard Medical School discussed methods of discovering longevity interventions, including analyzing the genomes of long-lived mammals and…

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. Jared Fischer of OHSU talked about senescent cancer cells and the intricate relationship between cancer and senescence. He talked about…

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. Huda Suliman of Icaria Life Sciences discussed her company’s role in the rejuvenation biotechnology ecosystem, including small molecule drug discovery…

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. John Lewis of Oisin Biotechnologies discussed senolytics, which are drugs that kill senescent cells. He explained the differences between healthy…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD